ArticleAmerican journal of clinical dermatology2021

Correction to: Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program.

Eric L Simpson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.